A 58-year-old male smoker presents with chest pain and is found to have a central lung mass on imaging. Bronchoscopic biopsy shows small, round cells with scant cytoplasm, coarse chromatin, and high mitotic rate. Immunohistochemistry is positive for chromogranin and synaptophysin. All of the following are true regarding this patient's likely diagnosis EXCEPT:

Explanation

## Small Cell Lung Cancer: Clinical Presentation & Management ### Central vs. Peripheral Location **Key Point:** SCLC characteristically arises from **central airways** (main, lobar, or segmental bronchi) and presents as a **central mass**, not peripheral. This is in contrast to adenocarcinoma, which is typically peripheral. **Clinical Pearl:** The central location of SCLC: - Causes early airway obstruction → cough, hemoptysis, post-obstructive pneumonia - Leads to hilar lymphadenopathy - Facilitates early invasion of mediastinal structures - Does NOT confer a better prognosis — in fact, central location correlates with advanced disease ### Staging & Metastatic Workup **High-Yield:** SCLC staging uses a **two-tier system**: - **Limited-stage (LS):** Tumor confined to one hemithorax + regional lymph nodes (can be encompassed in single radiation port) - **Extensive-stage (ES):** Distant metastases present **Mandatory staging investigations:** 1. **Brain MRI** — brain metastases in 25–50% at presentation 2. **CT chest/abdomen/pelvis** — liver and adrenal involvement 3. **Bone scan or PET-CT** — skeletal metastases 4. **Baseline labs** — LDH (prognostic marker), electrolytes (SIADH) ### Treatment Strategy **Key Point:** Limited-stage SCLC is treated with **concurrent platinum-based chemotherapy + thoracic radiotherapy**: - Chemotherapy: Cisplatin/carboplatin + etoposide (4–6 cycles) - Radiotherapy: Thoracic RT (45 Gy in 30 fractions) given concurrently with chemotherapy - Prophylactic cranial irradiation (PCI) if complete response achieved Extensive-stage: Chemotherapy ± immunotherapy (atezolizumab added to chemotherapy in responders). ### Why Option 3 is INCORRECT **Warning:** Option 3 falsely claims SCLC is **peripheral** with **better prognosis due to earlier detection**. This is the opposite of reality: | Feature | SCLC Reality | | --- | --- | | Location | **Central** (main/lobar bronchi) | | Detection timing | **Late** (>95% have regional/distant spread) | | Prognosis | **Worst** of all lung cancers (5-year OS ~7%) | | Why poor prognosis | Early metastatic spread, rapid chemoresistance | **Mnemonic: SCLC CENTRAL** — **C**entral location, **E**arly metastases, **N**euroendocrine origin, **T**horacic + chemo, **R**apid progression, **A**irway obstruction, **L**ate diagnosis, **B**rain involvement common